In 2014, The U.S. Centers for Disease Control and Prevention (“CDC”) reported there were an estimated 722,000 Healthcare Associated Infections (HAIs) in U.S. acute care hospitals. Additionally, about 75,000 patients per year with HAIs died during their hospitalizations. The CDC also reported the estimated annual cost of HAIs, not including legal fees, is between $35.7 billion and $45 billion.
HAI Bacterial Pathogens, including MRSA and E. coli, are able to survive on fabrics and textiles used in clinical settings. These Pathogens have the potential via touch contamination to be vectors for HAIs in healthcare environments.
Greg Judah spent eight years exploring and developing a bacteriostatic treatment to prevent the growth of bacterial Pathogens on fabric material. Mr. Judah’s technology has been confirmed by U.S. and international testing labs to be over 99% effective in reducing both gram negative and gram-positive bacteria. Even after 50 industrial washings, Mr. Judah’s process is over 99% effective for both MRSA and e-Coli. Mr. Judah’s technology is currently patent pending in the U.S. and a PCT application has been submitted.
The technology Mr. Judah developed has been proven in a manufacturing environment using existing equipment in an established textile mill. Thus, there is no need to obtain new capital equipment or set up a factory to produce the treated fabric. The fabric must be treated under heat and pressure as part of the normal milling process of the yarn. Upon completion of the fabric manufacturing, the material will be transferred to a sub contract cut and sew facility to produce the finished good. These subcontractors are well established and service large vendors in the industry.